(Press Release)
Adrian Stecyk serves as Chief Executive Officer of Myrtelle. He is co-founder of Myrtelle and in March 2024 accepted the role of CEO. Adrian has co-founded several gene therapy companies including Agilis Biotherapeutics which was acquired by PTC. He began his career at Draper Labs, a technology R&D company focused on design, development, and deployment of advanced technological solutions for some of the nation’s most challenging problems in security, space, healthcare, energy, and technology. Thereafter he co-founded Griffin Securities, and investment bank focused on assisting emerging biotechnology with financial and advisory support to advance the development of innovative research and technologies. Over the past 25 years he has help over 100 companies advance their research and development of products primarily in the biotechnology sector. Adrian has a B.S. in Aerospace Engineering and an M.B.A. in Finance from Boston University. His passion is to help people live better lives.
We cultivate strategic partnerships which allow us to further our mission through alliances in scientific research, development, manufacturing, and more, including an exclusive IP license with Pfizer Inc.
(Press Release)
(Gene Therapy)
(Canavan Disease)